ARTICLE | Financial News

Orexigen jumps as panel backs Contrave

December 9, 2010 12:10 AM UTC

Orexigen Therapeutics Inc. (NASDAQ:OREX) spiked $3.90 (80%) to $8.77 on Wednesday after an FDA advisory committee voted 13-7 on Tuesday that the benefit-risk profile of Contrave supports approval as a long-term treatment for obesity. The NDA for the fixed-dose combination of bupropion and naltrexone has a Jan. 31 PDUFA date. ...